1. Home
  2. ALLT vs STRO Comparison

ALLT vs STRO Comparison

Compare ALLT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$7.73

Market Cap

408.0M

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$21.93

Market Cap

381.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLT
STRO
Founded
1996
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
408.0M
381.1M
IPO Year
2006
2018

Fundamental Metrics

Financial Performance
Metric
ALLT
STRO
Price
$7.73
$21.93
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$12.40
$31.33
AVG Volume (30 Days)
243.1K
305.4K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$38,419,000.00
Revenue This Year
$15.84
N/A
Revenue Next Year
$12.09
N/A
P/E Ratio
$469.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.12
$0.72
52 Week High
$11.92
$43.85

Technical Indicators

Market Signals
Indicator
ALLT
STRO
Relative Strength Index (RSI) 47.73 40.80
Support Level $7.41 $18.74
Resistance Level $8.51 $27.16
Average True Range (ATR) 0.37 1.97
MACD -0.00 -0.08
Stochastic Oscillator 28.92 46.78

Price Performance

Historical Comparison
ALLT
STRO

About ALLT Allot Ltd.

Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: